Why Is Merck Stock Falling Tuesday?

All NewsApril 21, 2026

Merck stock falls as the Phase 3 LITESPARK-012 trial for advanced renal cell carcinoma fails to meet primary endpoints. Read the update.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent